Genmab A/SGenmab A/S - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

The webpage includes a questions and answers section on Genmab A/S. The ESG score includes 17 UN SDGs including: 'Clean Water & Sanitation', 'Decent Work & Economic Growth' and 'Peace, Justice & Strong Institutions'. The report of Genmab A/S incorporates data points from across the internet and also from available filings by Genmab A/S.

Genmab A/S in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.8; made up of an environmental score of 6.9, social score of 4.6 and governance score of 8.0.

SDG Transparency Score for Genmab A/S 
Low
0 - 3

6.8

Medium Impact
4 - 6
High
7 - 10
Last Score Update: 2023-07-01
What drives the score for Genmab A/S 
6.9

Environmental

4.6

Social

8.0

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Novartis AG
9.2
High
2Daiichi Sankyo Co Ltd
8.9
High
387Zim Laboratories Ltd
6.9
High
387YungShin Global Holding Corp
6.9
High
432Genmab A/S
6.8
High
432BLIS Technologies Ltd
6.8
High
432Aileron Therapeutics Inc
6.8
High
.........
2749Xynomic Pharmaceuticals Holdings Inc
0.0
Low
2749Zyden Gentec Ltd
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does Genmab A/S have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does Genmab A/S disclose current and historical energy intensity?

LockedSign up for free to unlock

Does Genmab A/S report the average age of the workforce?

LockedSign up for free to unlock

Does Genmab A/S reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does Genmab A/S disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does Genmab A/S disclose cybersecurity risks?

LockedSign up for free to unlock

Does Genmab A/S offer flexible work?

LockedSign up for free to unlock

Does Genmab A/S have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does Genmab A/S disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does Genmab A/S conduct supply chain audits?

LockedSign up for free to unlock

Does Genmab A/S disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does Genmab A/S conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does Genmab A/S disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does Genmab A/S disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does Genmab A/S disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does Genmab A/S disclose water use targets?

LockedSign up for free to unlock

Does Genmab A/S have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did Genmab A/S have a product recall in the last two years?

LockedSign up for free to unlock

Does Genmab A/S disclose incidents of discrimination?

LockedSign up for free to unlock

Does Genmab A/S allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has Genmab A/S issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does Genmab A/S disclose parental leave metrics?

LockedSign up for free to unlock

Does Genmab A/S disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does Genmab A/S disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does Genmab A/S disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does Genmab A/S support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does Genmab A/S disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does Genmab A/S reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is Genmab A/S involved in embryonic stem cell research?

LockedSign up for free to unlock

Does Genmab A/S disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does Genmab A/S disclose its waste policy?

LockedSign up for free to unlock

Does Genmab A/S report according to TCFD requirements?

LockedSign up for free to unlock

Does Genmab A/S disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does Genmab A/S disclose energy use targets?

LockedSign up for free to unlock

Does Genmab A/S disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does Genmab A/S have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for Genmab A/S
These potential risks are based on the size, segment and geographies of the company.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Sorry!

Failed to process!